TY - JOUR T1 - Cyfra 21-1 as a Serum Tumor Marker for Follow-up of Patients with Laryngeal and Hypopharyngeal Squamous Cell Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 3421 LP - 3425 VL - 29 IS - 8 AU - HANI AL-SHAGAHIN AU - KHALED ALKOTYFAN AU - HANS-HELGE MÜLLER AU - ANDREAS M. SESTERHENN AU - JOCHEN. A. WERNER Y1 - 2009/08/01 UR - http://ar.iiarjournals.org/content/29/8/3421.abstract N2 - Aim: To evaluate the importance and potential of Cyfra21-1 as a tumor marker (TM) for follow-up of patients with squamous cell carcinoma (SCC) in laryngeal and hypopharyngeal cancer. Patients and Methods: Cyfra21-1 serum levels of 50 patients with laryngeal and hypopharyngeal SCC were evaluated by ECLIA assay. Statistical analysis was performed using Kruskal-Wallis and Jonckheere-Terpstra tests. Results: There was no significant correlation between Cyfra21-1 levels at the time of initial diagnosis and the clinicopathological parameters. The clinical performance of Cyfra 21-1 as an individual tumor marker for follow-up of patients was good. This is shown by the area under the curve (0.873) of their receiver operating characteristic curves. The sensitivity and specificity of Cyfra 21-1 at a cut-off 3.3 ng/ml ere 61.1% and 96.9% respectively. Conclusion: Cyfra 21-1 is not suitable for early diagnosis of SCC of the larynx and hypopharynx. An abrupt increase of Cyfra 21-1 in serial measurements indicates impending disease progression in individual patients. ER -